Trinity Biotech Announces Q2 2024 Financial Results
TRIBTrinity Biotech(TRIB) GlobeNewswire News Room·2024-08-14 19:30

-Q2, 2024 total revenues of 15.8milliongrew+1415.8 million grew +14% Y/Y and +7.7% Q/Q based on strong demand and output in the TrinScreen HIV business- -Point-of-Care product revenue of 4.6 million grew 119% Y/Y and +53% Q/Q- -Reiterating guidance to achieve approximately 20millionofannualizedrun−rateEBITDASO1onannualizedrun−raterevenuesofapproximately20 million of annualized run-rate EBITDASO1 on annualized run-rate revenues of approximately 75 million by Q2, 2025- DUBLIN, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on human ...